Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer.
- Author:
Xiang-Ru ZHANG
1
;
Yun-Zhong ZHU
;
Qing-Yu XIU
;
Fu-Cai HAN
;
Duan-Qi LIU
;
Da-Tong CHU
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Alopecia; chemically induced; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Camptothecin; administration & dosage; adverse effects; analogs & derivatives; Carcinoma, Non-Small-Cell Lung; drug therapy; mortality; pathology; Cisplatin; administration & dosage; adverse effects; Diarrhea; chemically induced; Female; Humans; Lung Neoplasms; drug therapy; mortality; pathology; Male; Middle Aged; Neoplasm Staging; Neutropenia; chemically induced; Remission Induction; Survival Rate
- From: Chinese Journal of Oncology 2006;28(10):777-779
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and adverse events of irinotecan (CPT-11) combined with cisplatin (DDP) in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
METHODSOf 36 NSCLC patients consisting of 23 males and 13 females with a medium age of 52 years included, there were 26 adenocarcinomas, 7 squamous cell carcinomas, 1 adeno-squamous cell carcinoma and 2 unclassified types; 13 stage III B and 23 stage IV; 24 chemonaive and 12 previously treated by chemotherapy with a medium Karnofsky status of 90. All patients had measurable or evaluable parameters. The regimen was administered as following: CPT-11 60 mg/m2, IV, D1, 8 and 15; DDP 80 mg/m2, IV, D1; every 28 days as a cycle.
RESULTSTotally, 97 cycles were carried out in these 36 patients with a medium cycles of 3. Of 35 evaluable patients, 22.9% (8/35) achieved partial response, 60.0% (21/35) had stable disease and 17.1% (6/35) progressive disease. The response rate was 29.2% (7/24) for chemonaive patients and 9.1% (1/11) for these previously treated. The 1-year survival rate was 45.4% with a medium time to tumor progression (TTP) of 199 days for the responders. The incidence rate of grade III/IV adverse events were: 16.7% for neutropenia, 13.9% alopecia, 5.6% diarrhea, 2.8% nausea and vomiting, respectively.
CONCLUSIONIrinotecan plus cisplatin is effective with tolerable adverse events in treating patients with advanced non-small cell lung cancer, but further investigation trials are needed.